Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 420

1.

Guselkumab efficacy after withdrawal is associated with suppression of serum IL-23-regulated IL-17 and IL-22 in psoriasis: VOYAGE 2 study.

Gordon KB, Armstrong AW, Foley P, Song M, Shen YK, Li S, Muñoz-Elías EJ, Branigan P, Liu X, Reich K.

J Invest Dermatol. 2019 Jun 14. pii: S0022-202X(19)31755-5. doi: 10.1016/j.jid.2019.05.016. [Epub ahead of print]

PMID:
31207232
2.

Evidence-Based Psychotherapy Interventions to Improve Psychosocial Functioning in Veterans With PTSD: An Integrative Review.

Reich K, Nemeth L, Acierno R.

J Psychosoc Nurs Ment Health Serv. 2019 Jun 11:1-10. doi: 10.3928/02793695-20190531-04. [Epub ahead of print]

PMID:
31188457
3.

Secukinumab dosing optimization in patients with moderate to severe plaque psoriasis: Results from the randomised, open-label OPTIMISE study.

Reich K, Puig L, Szepietowski JC, Paul C, Lacour JP, Tsianakas A, Sieder C, Rissler M, Pournara E, Orsenigo R.

Br J Dermatol. 2019 May 17. doi: 10.1111/bjd.18143. [Epub ahead of print]

PMID:
31102257
4.

Smoking does not Alter the Therapy Response to Systemic Anti-psoriatic Therapies: A Two-country, Multi-centre, Prospective, Non-interventional Study.

Anzengruber F, Augustin M, Radtke MA, Thaci D, Yawalkar N, Streit M, Reich K, Drach M, Sorbe C, French LE, Mrowietz U, Maul JT, Itin PH, Navarini AA.

Acta Derm Venereol. 2019 May 17. doi: 10.2340/00015555-3221. [Epub ahead of print]

5.

Prise en charge du trouble de consommation d’opioïdes en première ligne: Lignes directrices simplifiées de PEER.

Korownyk C, Perry D, Ton J, Kolber MR, Garrison S, Thomas B, Allan GM, Bateman C, de Queiroz R, Kennedy D, Lamba W, Marlinga J, Mogus T, Nickonchuk T, Orrantia E, Reich K, Wong N, Dugré N, Lindblad AJ.

Can Fam Physician. 2019 May;65(5):e173-e184. French.

PMID:
31088882
Free PMC Article
6.

Managing opioid use disorder in primary care: PEER simplified guideline.

Korownyk C, Perry D, Ton J, Kolber MR, Garrison S, Thomas B, Allan GM, Bateman C, de Queiroz R, Kennedy D, Lamba W, Marlinga J, Mogus T, Nickonchuk T, Orrantia E, Reich K, Wong N, Dugré N, Lindblad AJ.

Can Fam Physician. 2019 May;65(5):321-330.

7.

Use of dose-exposure-response relationships in Phase 2 and Phase 3 guselkumab studies to optimize dose selection in psoriasis.

Lebwohl M, Langley RG, Zhu Y, Zhou H, Song M, Shen YK, Parnell Lafferty K, Reich K.

J Eur Acad Dermatol Venereol. 2019 May 11. doi: 10.1111/jdv.15668. [Epub ahead of print]

PMID:
31077471
8.

Long-term safety of secukinumab in patients with moderate-to-severe plaque psoriasis, psoriatic arthritis, and ankylosing spondylitis: integrated pooled clinical trial and post-marketing surveillance data.

Deodhar A, Mease PJ, McInnes IB, Baraliakos X, Reich K, Blauvelt A, Leonardi C, Porter B, Das Gupta A, Widmer A, Pricop L, Fox T.

Arthritis Res Ther. 2019 May 2;21(1):111. doi: 10.1186/s13075-019-1882-2.

9.

Switching from a fumaric acid ester mixture to dimethylfumarate monotherapy in psoriasis.

Warren RB, Barker JNW, Van de Kerkhof P, Reich K, Mrowietz U.

J Eur Acad Dermatol Venereol. 2019 Apr 29. doi: 10.1111/jdv.15644. [Epub ahead of print] No abstract available.

PMID:
31033034
10.

Secukinumab, a fully human anti-interleukin-17A monoclonal antibody, exhibits low immunogenicity in psoriasis patients treated up to 5 years.

Reich K, Blauvelt A, Armstrong A, Langley RG, de Vera A, Kolbinger F, Spindeldreher S, Ren M, Bruin G.

J Eur Acad Dermatol Venereol. 2019 Apr 22. doi: 10.1111/jdv.15637. [Epub ahead of print]

PMID:
31009130
11.

Continued treatment with secukinumab is associated with high retention or regain of response.

Augustin M, Thaci D, Eyerich K, Pinter A, Radtke M, Lauffer F, Mrowietz U, Gerdes S, Pariser D, Lebwohl M, Sieder C, Melzer N, Reich K.

Br J Dermatol. 2019 Apr 10. doi: 10.1111/bjd.17991. [Epub ahead of print]

PMID:
30972746
12.

Clinical response of psoriasis to subcutaneous methotrexate correlates with inhibition of cutaneous Th1- and Th17-inflammatory pathways.

Reich K, Reich JLK, Falk TM, Blödorn-Schlicht N, Mrowietz U, von Kiedrowski R, Pfeiffer C, Niesmann J, Frambach Y, Warren RB.

Br J Dermatol. 2019 Apr 10. doi: 10.1111/bjd.18001. [Epub ahead of print]

PMID:
30972731
13.

Assessment of the effects of immunogenicity on the pharmacokinetics, efficacy and safety of tildrakizumab.

Kimball AB, Kerbusch T, van Aarle F, Kulkarni P, Li Q, Blauvelt A, Papp KA, Reich K, Montgomery D.

Br J Dermatol. 2019 Mar 27. doi: 10.1111/bjd.17918. [Epub ahead of print]

PMID:
30916381
14.

Histomorphometric Analysis of Callus Formation Stimulated by Axial Dynamisation in a Standardised Ovine Osteotomy Model.

Reich KM, Tangl S, Heimel P, Lettner S, Ignatius A, Claes LE, Pfeil J, Janousek A, Redl H.

Biomed Res Int. 2019 Feb 12;2019:4250940. doi: 10.1155/2019/4250940. eCollection 2019.

15.

Efficacy of tildrakizumab for moderate-to-severe plaque psoriasis: pooled analysis of three randomized controlled trials at weeks 12 and 28.

Papp KA, Reich K, Blauvelt A, Kimball AB, Gooderham M, Tyring SK, Sinclair R, Thaci D, Li Q, Cichanowitz N, Green S, La Rosa C.

J Eur Acad Dermatol Venereol. 2019 Jun;33(6):1098-1106. doi: 10.1111/jdv.15400. Epub 2019 Mar 5.

PMID:
30838709
16.

Efficacy and safety of mirikizumab (LY3074828) in the treatment of moderate-to-severe plaque psoriasis: results from a randomized phase II study.

Reich K, Rich P, Maari C, Bissonnette R, Leonardi C, Menter A, Igarashi A, Klekotka P, Patel D, Li J, Tuttle J, Morgan-Cox M, Edson-Heredia E, Friedrich S, Papp K; AMAF investigators.

Br J Dermatol. 2019 Feb 7. doi: 10.1111/bjd.17628. [Epub ahead of print]

PMID:
30734266
17.

Mindfulness-based Stress Reduction in Pregnancy: an App-Based Programme to Improve the Health of Mothers and Children (MINDFUL/PMI Study).

Lenz B, Eichler A, Schwenke E, Buchholz VN, Hartwig C, Moll GH, Reich K, Mühle C, Volz B, Titzmann A, Beckmann MW, Heinrich H, Kornhuber J, Fasching PA.

Geburtshilfe Frauenheilkd. 2018 Dec;78(12):1283-1291. doi: 10.1055/a-0677-2630. Epub 2018 Dec 14.

18.

Incidence rates of inflammatory bowel disease in patients with psoriasis, psoriatic arthritis and ankylosing spondylitis treated with secukinumab: a retrospective analysis of pooled data from 21 clinical trials.

Schreiber S, Colombel JF, Feagan BG, Reich K, Deodhar AA, McInnes IB, Porter B, Das Gupta A, Pricop L, Fox T.

Ann Rheum Dis. 2019 Apr;78(4):473-479. doi: 10.1136/annrheumdis-2018-214273. Epub 2019 Jan 23.

19.

Impact of Secukinumab on Endothelial Dysfunction and Other Cardiovascular Disease Parameters in Psoriasis Patients over 52 Weeks.

von Stebut E, Reich K, Thaçi D, Koenig W, Pinter A, Körber A, Rassaf T, Waisman A, Mani V, Yates D, Frueh J, Sieder C, Melzer N, Mehta NN, Gori T.

J Invest Dermatol. 2019 May;139(5):1054-1062. doi: 10.1016/j.jid.2018.10.042. Epub 2018 Nov 30.

20.

Safety of guselkumab in patients with moderate-to-severe psoriasis treated through 100 weeks: a pooled analysis from the randomized VOYAGE 1 and VOYAGE 2 studies.

Reich K, Papp KA, Armstrong AW, Wasfi Y, Li S, Shen YK, Randazzo B, Song M, Kimball AB.

Br J Dermatol. 2019 May;180(5):1039-1049. doi: 10.1111/bjd.17454.

PMID:
30485400
21.

The Influence of Type 2 Diabetes Mellitus on the Osseointegration of Titanium Implants With Different Surface Modifications-A Histomorphometric Study in High-Fat Diet/Low-Dose Streptozotocin-Treated Rats.

Zhou W, Tangl S, Reich KM, Kirchweger F, Liu Z, Zechner W, Christian Ulm, Rausch-Fan X.

Implant Dent. 2019 Feb;28(1):11-19. doi: 10.1097/ID.0000000000000836.

PMID:
30461438
22.

Topology of psoriasis in routine care: results from high-resolution analysis of 2009 patients.

Augustin M, Sommer R, Kirsten N, Danckworth A, Radtke MA, Reich K, Thaci D, Boehncke WH, Langenbruch A, Mrowietz U.

Br J Dermatol. 2018 Nov 14. doi: 10.1111/bjd.17403. [Epub ahead of print]

PMID:
30430557
23.
24.

Gender and age significantly determine patient needs and treatment goals in psoriasis - a lesson for practice.

Maul JT, Navarini AA, Sommer R, Anzengruber F, Sorbe C, Mrowietz U, Drach M, Blome C, Boehncke WH, Thaci D, Reich K, von Kiedrowski R, Körber A, Yawalkar N, Mainetti C, Laffitte E, Streit M, Rustenbach S, Conrad C, Borradori L, Gilliet M, Cozzio A, Itin P, Häusermann P, French LE, Radtke MA, Augustin M.

J Eur Acad Dermatol Venereol. 2019 Apr;33(4):700-708. doi: 10.1111/jdv.15324. Epub 2019 Jan 15.

PMID:
30388318
25.

Effect of secukinumab on the clinical activity and disease burden of nail psoriasis: 32-week results from the randomized placebo-controlled TRANSFIGURE trial.

Reich K, Sullivan J, Arenberger P, Mrowietz U, Jazayeri S, Augustin M, Parneix A, Regnault P, You R, Milutinovic M.

Br J Dermatol. 2018 Oct 26. doi: 10.1111/bjd.17351. [Epub ahead of print]

PMID:
30367462
26.

Immunoglobulin E-Selective Immunoadsorption Reduces Peripheral and Skin-Bound Immunoglobulin E and Modulates Cutaneous IL-13 Expression in Severe Atopic Dermatitis.

Reich K, Hartjen A, Reich J, Schröder J, Steingrube N, Bresch M, Ertas B, Falk TM, Blödorn-Schlicht N, Jäckle S, Meier M.

J Invest Dermatol. 2019 Mar;139(3):720-723. doi: 10.1016/j.jid.2018.09.020. Epub 2018 Oct 24. No abstract available.

27.

Definition of psoriasis severity in routine clinical care: current guidelines fail to capture the complexity of long-term psoriasis management.

Augustin M, Langenbruch A, Gutknecht M, Reich K, Körber A, Maaßen D, Mrowietz U, Thaçi D, von Kiedrowski R, Radtke MA.

Br J Dermatol. 2018 Dec;179(6):1385-1391. doi: 10.1111/bjd.17128. Epub 2018 Oct 17.

PMID:
30334253
28.

Measuring Patient Needs and Benefits in Dermatology using the Patient Benefit Index 2.0: A Validation Study.

Topp J, Augustin M, von Usslar K, Gosau R, Reich K, Reusch M, Blome C.

Acta Derm Venereol. 2019 Feb 1;99(2):211-217. doi: 10.2340/00015555-3063.

29.

Certolizumab pegol for the treatment of patients with moderate-to-severe chronic plaque psoriasis: pooled analysis of week 16 data from three randomized controlled trials.

Blauvelt A, Reich K, Lebwohl M, Burge D, Arendt C, Peterson L, Drew J, Rolleri R, Gottlieb AB.

J Eur Acad Dermatol Venereol. 2019 Mar;33(3):546-552. doi: 10.1111/jdv.15258. Epub 2018 Oct 14.

PMID:
30242918
30.

Clinical use of dimethyl fumarate in moderate-to-severe plaque-type psoriasis: a European expert consensus.

Mrowietz U, Barker J, Boehncke WH, Iversen L, Kirby B, Naldi L, Reich K, Tanew A, van de Kerkhof PCM, Warren RB.

J Eur Acad Dermatol Venereol. 2018 Oct;32 Suppl 3:3-14. doi: 10.1111/jdv.15218. Epub 2018 Sep 20.

PMID:
30238510
31.

Long-term safety profile of ixekizumab in patients with moderate-to-severe plaque psoriasis: an integrated analysis from 11 clinical trials.

Langley RG, Kimball AB, Nak H, Xu W, Pangallo B, Osuntokun OO, Agada N, Reich K.

J Eur Acad Dermatol Venereol. 2019 Feb;33(2):333-339. doi: 10.1111/jdv.15242. Epub 2018 Nov 22.

PMID:
30198588
32.

Ixekizumab provides superior efficacy compared with ustekinumab over 52 weeks of treatment: Results from IXORA-S, a phase 3 study.

Paul C, Griffiths CEM, van de Kerkhof PCM, Puig L, Dutronc Y, Henneges C, Dossenbach M, Hollister K, Reich K.

J Am Acad Dermatol. 2019 Jan;80(1):70-79.e3. doi: 10.1016/j.jaad.2018.06.039. Epub 2018 Jun 30.

PMID:
29969700
33.

Secukinumab in pregnancy: outcomes in psoriasis, psoriatic arthritis and ankylosing spondylitis from the global safety database.

Warren RB, Reich K, Langley RG, Strober B, Gladman D, Deodhar A, Bachhuber T, Bao W, Altemeyer E, Hussain S, Safi J Jr.

Br J Dermatol. 2018 Nov;179(5):1205-1207. doi: 10.1111/bjd.16901. Epub 2018 Sep 11. No abstract available.

PMID:
29927479
34.

Exposure-Response Modeling to Characterize the Relationship Between Ixekizumab Serum Drug Concentrations and Efficacy Responses at Week 12 in Patients With Moderate to Severe Plaque Psoriasis.

Chigutsa E, Velez de Mendizabal N, Chua L, Heathman M, Friedrich S, Jackson K, Reich K.

J Clin Pharmacol. 2018 Nov;58(11):1489-1500. doi: 10.1002/jcph.1268. Epub 2018 Jun 7.

PMID:
29878382
35.

Was ist Schuppenflechte? - Wahrnehmung und Bewertung der Psoriasis in der deutschen Bevölkerung.

Sommer R, Mrowietz U, Radtke MA, Schäfer I, von Kiedrowski R, Strömer K, Enk A, Maul JT, Reich K, Zander N, Augustin M.

J Dtsch Dermatol Ges. 2018 Jun;16(6):703-710. doi: 10.1111/ddg.13539_g.

PMID:
29873919
36.

S3 Guideline for the treatment of psoriasis vulgaris, update - Short version part 2 - Special patient populations and treatment situations.

Nast A, Amelunxen L, Augustin M, Boehncke WH, Dressler C, Gaskins M, Härle P, Hoffstadt B, Klaus J, Koza J, Mrowietz U, Ockenfels HM, Philipp S, Reich K, Rosenbach T, Rzany B, Schlaeger M, Schmid-Ott G, Sebastian M, von Kiedrowski R, Weberschock T.

J Dtsch Dermatol Ges. 2018 Jun;16(6):806-813. doi: 10.1111/ddg.13538.

PMID:
29873906
37.

S3-Leitlinie zur Therapie der Psoriasis vulgaris Update - Kurzfassung Teil 2 - Besondere Patientengruppen und spezielle Behandlungssituationen.

Nast A, Amelunxen L, Augustin M, Boehncke WH, Dressler C, Gaskins M, Härle P, Hoffstadt B, Klaus J, Koza J, Mrowietz U, Ockenfels HM, Philipp S, Reich K, Rosenbach T, Rzany B, Schlaeger M, Schmid-Ott G, Sebastian M, von Kiedrowski R, Weberschock T.

J Dtsch Dermatol Ges. 2018 Jun;16(6):806-814. doi: 10.1111/ddg.13538_g.

PMID:
29873903
38.

What is psoriasis? - Perception and assessment of psoriasis among the German population.

Sommer R, Mrowietz U, Radtke MA, Schäfer I, von Kiedrowski R, Strömer K, Enk A, Maul JT, Reich K, Zander N, Augustin M.

J Dtsch Dermatol Ges. 2018 Jun;16(6):703-710. doi: 10.1111/ddg.13539.

PMID:
29873901
39.

Ixekizumab Pharmacokinetics, Anti-Drug Antibodies, and Efficacy through 60 Weeks of Treatment of Moderate to Severe Plaque Psoriasis.

Reich K, Jackson K, Ball S, Garces S, Kerr L, Chua L, Muram TM, Blauvelt A.

J Invest Dermatol. 2018 Oct;138(10):2168-2173. doi: 10.1016/j.jid.2018.04.019. Epub 2018 May 8.

40.

S3-Leitlinie zur Therapie der Psoriasis vulgaris Update - Kurzfassung Teil 1 - Systemische Therapie.

Nast A, Amelunxen L, Augustin M, Boehncke WH, Dressler C, Gaskins M, Härle P, Hoffstadt B, Klaus J, Koza J, Mrowietz U, Ockenfels HM, Philipp S, Reich K, Rosenbach T, Rzany B, Schlaeger M, Schmid-Ott G, Sebastian M, von Kiedrowski R, Weberschock T.

J Dtsch Dermatol Ges. 2018 May;16(5):645-670. doi: 10.1111/ddg.13516_g. No abstract available.

PMID:
29750455
41.

S3 Guideline for the treatment of psoriasis vulgaris, update - Short version part 1 - Systemic treatment.

Nast A, Amelunxen L, Augustin M, Boehncke WH, Dressler C, Gaskins M, Härle P, Hoffstadt B, Klaus J, Koza J, Mrowietz U, Ockenfels HM, Philipp S, Reich K, Rosenbach T, Rzany B, Schlaeger M, Schmid-Ott G, Sebastian M, von Kiedrowski R, Weberschock T.

J Dtsch Dermatol Ges. 2018 May;16(5):645-669. doi: 10.1111/ddg.13516.

PMID:
29750443
42.

Safety of tildrakizumab for moderate-to-severe plaque psoriasis: pooled analysis of three randomized controlled trials.

Blauvelt A, Reich K, Papp KA, Kimball AB, Gooderham M, Tyring SK, Sinclair R, Thaçi D, Li Q, Cichanowitz N, Green S, La Rosa C.

Br J Dermatol. 2018 Sep;179(3):615-622. doi: 10.1111/bjd.16724. Epub 2018 Jul 4.

PMID:
29742274
43.

Anxiety and depression in patients with moderate-to-severe psoriasis and comparison of change from baseline after treatment with guselkumab vs. adalimumab: results from the Phase 3 VOYAGE 2 study.

Gordon KB, Armstrong AW, Han C, Foley P, Song M, Wasfi Y, You Y, Shen YK, Reich K.

J Eur Acad Dermatol Venereol. 2018 Nov;32(11):1940-1949. doi: 10.1111/jdv.15012. Epub 2018 Jul 18.

PMID:
29706008
44.

Certolizumab pegol for the treatment of chronic plaque psoriasis: Results through 48 weeks from 2 phase 3, multicenter, randomized, double-blinded, placebo-controlled studies (CIMPASI-1 and CIMPASI-2).

Gottlieb AB, Blauvelt A, Thaçi D, Leonardi CL, Poulin Y, Drew J, Peterson L, Arendt C, Burge D, Reich K.

J Am Acad Dermatol. 2018 Aug;79(2):302-314.e6. doi: 10.1016/j.jaad.2018.04.012. Epub 2018 Apr 13.

45.

Safety and Tolerability of Ixekizumab: Integrated Analysis of Injection-Site Reactions from 11 Clinical Trials.

Shear NH, Paul C, Blauvelt A, Gooderham M, Leonardi C, Reich K, Ohtsuki M, Pangallo B, Xu W, Ball S, Ridenour T, Torisu-Itakura H, Agada N, Mallbris L.

J Drugs Dermatol. 2018 Feb 1;17(2):200-206.

PMID:
29462229
46.

Safety and efficacy of apremilast through 104 weeks in patients with moderate to severe psoriasis who continued on apremilast or switched from etanercept treatment: findings from the LIBERATE study.

Reich K, Gooderham M, Bewley A, Green L, Soung J, Petric R, Marcsisin J, Cirulli J, Chen R, Piguet V.

J Eur Acad Dermatol Venereol. 2018 Mar;32(3):397-402. doi: 10.1111/jdv.14738. Epub 2018 Jan 29.

47.

Dupilumab with concomitant topical corticosteroid treatment in adults with atopic dermatitis with an inadequate response or intolerance to ciclosporin A or when this treatment is medically inadvisable: a placebo-controlled, randomized phase III clinical trial (LIBERTY AD CAFÉ).

de Bruin-Weller M, Thaçi D, Smith CH, Reich K, Cork MJ, Radin A, Zhang Q, Akinlade B, Gadkari A, Eckert L, Hultsch T, Chen Z, Pirozzi G, Graham NMH, Shumel B.

Br J Dermatol. 2018 May;178(5):1083-1101. doi: 10.1111/bjd.16156. Epub 2018 Mar 25.

48.

Histology and Serum Cytokine Responses in an Imported Rickettsia slovaca Infection, Germany.

Tappe D, Booken N, Böer-Auer A, Rauch J, Schmiedel S, Reich K.

Am J Trop Med Hyg. 2018 Jan;98(1):248-251. doi: 10.4269/ajtmh.17-0392.

49.

Extensive hyperpigmentation of the face in a Filipina.

Pirrone J, Broyer J, Otte N, Reich K, Boer-Auer A.

J Dtsch Dermatol Ges. 2017 Nov;15(11):1167-1168. doi: 10.1111/ddg.13329. Epub 2017 Oct 10. No abstract available.

PMID:
29024494
50.

Correction to: Digestive system in psoriasis: an update.

Pietrzak D, Pietrzak A, Krasowska D, Borzęcki A, Franciszkiewicz-Pietrzak K, Polkowska-Pruszyńska B, Baranowska M, Reich K.

Arch Dermatol Res. 2017 Nov;309(9):695-696. doi: 10.1007/s00403-017-1788-2.

PMID:
29018877

Supplemental Content

Support Center